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Understanding the in vivo fate of vaccine antigens and adjuvants and their safety is
crucial for the rational design of mucosal subunit vaccines. Prime and pull vaccination
using the T helper 17-inducing adjuvant CAF01 administered parenterally and mucosally,
respectively, has previously been suggested as a promising strategy to redirect immunity
to mucosal tissues. Recently, we reported a promising tuberculosis (TB) vaccination
strategy comprising of parenteral priming followed by intrapulmonary (i.pulmon.)
mucosal pull immunization with the TB subunit vaccine candidate H56/CAF01, which
resulted in the induction of lung-localized, H56-specific T cells and systemic as well as
lung mucosal IgA responses. Here, we investigate the uptake of H56/CAF01 by mucosal
and systemic innate myeloid cells, antigen-presenting cells (APCs), lung epithelial cells
and endothelial cells in mice after parenteral prime combined with i.pulmon. pull
immunization, and after parenteral or i.pulmon. prime immunization alone. We find that
i.pulmon. pull immunization of mice with H56/CAF01, which are parenterally primed
with H56/CAF01, substantially enhances vaccine uptake and presentation by pulmonary
and splenic APCs, pulmonary endothelial cells and type I epithelial cells and induces
stronger activation of dendritic cells in the lung-draining lymph nodes, compared with
parenteral immunization alone, which suggests activation of both innate and memory
responses. Using mass spectrometry imaging of lipid biomarkers, we further show that
(i) airway mucosal immunization with H56/CAF01 neither induces apparent local tissue
damage nor inflammation in the lungs, and (ii) the presence of CAF01 is accompanied
by evidence of an altered phagocytic activity in alveolar macrophages, evident from
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co-localization of CAF01 with the biomarker bis(monoacylglycero)phosphate, which
is expressed in the late endosomes and lysosomes of phagocytosing macrophages.
Hence, our data demonstrate that innate myeloid responses differ after one and two
immunizations, respectively, and the priming route and boosting route individually affect
this outcome. These findings may have important implications for the design of mucosal
vaccines intended for safe administration in the airways.
Keywords: H56/CAF01, tuberculosis, subunit vaccine, pulmonary administration, myeloid cells, antigen-
presenting cells, mass spectrometry imaging, drug delivery
INTRODUCTION
Tuberculosis (TB) is one of the top 10 causes of death worldwide,
and the disease killed an estimated 1.3 million people in 2017
(1). Approximately one fourth of the world’s population is
latently infected with Mycobacterium tuberculosis (Mtb), and
these individuals remain susceptible to active TB for the rest
of their life (1). With the emergence of multi-drug resistant
Mtb strains, a novel vaccine, which is more effective than the
currently available Bacillus Calmette-Guérin (BCG) vaccine, is
required to achieve the World Health Organization’s important
goal of ending the global TB epidemic by 2035 (2). In this respect,
mucosal delivery via intrapulmonary (i.pulmon.) administration
of subunit vaccines having excellent safety profiles (3, 4) is
a promising strategy to induce protective lung-localized Mtb-
specific T-cell responses (5). However, little is known about
the in vivo fate of inhaled vaccine antigens and adjuvants,
and their safety.
Innate myeloid cells include mononuclear phagocytes,
monocytes, dendritic cells (DCs), and granulocytes. These cells
play essential roles in pathogen clearance, initiation, regulation
and resolution of inflammation, and antigen presentation
(6, 7). Following repeated immunizations, i.e., prime – pull
immunization strategies, there is a continuous cross-talk between
innate and adaptive immune cells and vaccine components.
Hence, knowledge about these events is crucial to improve
the immunogenicity, protective efficacy and safety of vaccines.
Recent advances in the understanding of the diversity of myeloid
and non-myeloid antigen-presenting cells (APCs) clearly suggest
that for vaccines to induce specific immune profiles, they should
be targeted to immune cell subsets capable of inducing that
specific type of immune response (8, 9). For different subunit
vaccines administered i.pulmon., inconsistencies exist in the
immune responses they induce, and these differences may be
due to factors like (i) the diversified localization of different APC
subsets in the respiratory tract and the lung-draining lymph
nodes (LNs), (ii) their functional differences, (iii) the size of the
antigen, and (iv) the physicochemical properties of the adjuvant
(10–13). Therefore, an understanding of the initial interactions
taking place between the vaccine [antigen(s) and adjuvant]
and the immune system is crucial for the rational design of
safe vaccines, which have the capability to induce long-lasting
protective immunity in the lungs (14).
The subunit vaccine antigen H56 is a fusion protein
composed of the Mtb antigens Ag85B, ESAT-6, and Rv2660c,
and in combination with the cationic adjuvant formulation
01 (CAF01) administered parenterally, this antigen elicits a
polyfunctional Th1/Th17 CD4+ T cell response and causes
a significant reduction in Mtb burden (15–17). CAF01 is
composed of cationic liposomes based on the surfactant
dimethyldioctadecylammonium (DDA) bromide and the
glycolipid trehalose-6,6’-dibehenate (TDB) (18). CAF01 delivers
antigen and activates DCs (19), induces both humoral and
cell-mediated memory immune responses, and it has been tested
in phase I clinical trials, demonstrating an excellent safety and
immunogenicity profile (20–22). Our recent data suggests that
a parenteral prime – mucosal pull immunization strategy using
CAF01 can be applied to redirect immunity to mucosal tissues
(23). Recently, we reported an immunization strategy comprising
intramuscular (i.m.) priming followed by i.pulmon. mucosal
pull immunization with the H56/CAF01 vaccine, which resulted
in the induction of lung-localized, H56-specific T cells and
systemic as well as lung mucosal IgA responses (24). However,
the role of (i) H56/CAF01 deposition within lung tissue, (ii)
CAF01 internalization by phagocytic cells, and (iii) antigen
presentation in the lungs and the lung-draining LNs on the
induction of immune responses after pulmonary administration
are unknown. In addition, an outstanding research question is
the safety of CAF01 upon pulmonary administration.
Here, we applied multicolor flow cytometry to investigate
H56/CAF01 uptake by innate myeloid cells and APCs in
the lungs, the spleen, and the lung-draining LNs in mice
after i.m. or i.pulmon. prime or i.m. prime – i.pulmon.
pull immunization. We compared homologous prime – pull
immunization with prime immunization alone to examine if pre-
existing systemic H56-specific immunity induced by H56/CAF01
leads to different safety issues as compared to pulmonary prime
immunization alone. We did not include mucosal prime –
boost immunization as previous studies have showed no overt
immunological advantage applying this immunization strategy
(25). Mass spectrometry imaging (MSI) was used to follow
the time-dependent biodistribution of CAF01 and selected lipid
biomarkers in lung tissue.
MATERIALS AND METHODS
Materials
Dimethyldioctadecylammonium was obtained from Avanti
Polar Lipids (Alabaster, AL, United States). TDB was purchased
from Niels Clauson-Kaas A/S (Farum, Denmark). Xenolight
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1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide
(DiR) near infra-red fluorescent dye was purchased from
Perkin Elmer (Waltham, MA, United States). H56 protein
was produced recombinantly in E. coli as previously described
(15), reconstituted in 20 mM glycine buffer (pH 8.8), checked
for purity, and validated for residual DNA, endotoxins and
bioburden following internal good manufacturing practice
standards at Statens Serum Institut as described previously (16).
Alexa Fluor R© 647-labeling of H56 was performed commercially
(Thermo Fischer Scientific, Eugene, OR, United States). 2,5-
dihydroxybenzoic (DHB), 1,5-diaminonaphthalene (DAN),
trifluoroacetic acid (TFA), and Meyer’s hematoxylin solution and
eosin (H&E) solution were purchased from Sigma-Aldrich (St.
Louis, MO, United States). Methanol was obtained from Th.
Geyer (Renningen, Germany). Water was prepared by using a
Millipore Direct-Q3 UV system (Billerica, MA, United States).
All other chemicals and reagents were of analytical grade and
were acquired from commercial suppliers.
Preparation of CAF01
Liposomes were prepared by using the thin film method and
characterized for average intensity-weighted hydrodynamic
diameter (z-average), polydispersity index (PDI) and zeta-
potential as previously described (24). Briefly, weighed
amounts of DDA and TDB (5:1, w/w) were dissolved in
chloroform/methanol (9:1, v/v) in a round bottom flask. The
lipid mixture was dried overnight by rotary evaporation under
vacuum after cleaning with 99% (v/v) ethanol. The lipid film
was rehydrated in 10 mM Tris buffer (pH 7.4), sonicated for
5 min using an ultrasound cleaner (Branson Ultrasonic Cleaner,
Danburry, CT, United States), and heated to 60◦C for 1 h
in a water bath with vortexing every 10 min. The liposomes
were tip-sonicated for 20 s, 20 min after the rehydration by
using a MISONIX S-4000 probe sonicator (LLC, Newtown,
CT, United States) (amplitude 70; power 16 W) to reduce their
size. The final concentration of CAF01 was 20/4 mg/mL of
DDA/TDB, corresponding to a molar ratio of 89:11. Solutions
of unlabeled or Alexa Fluor R© 647-labeled H56 were mixed with
equal volumes of CAF01 dispersions at concentrations of 5
and 10 µg/mL, respectively, and the antigen was allowed to
adsorb to the liposomes for 30 min at room temperature before
administration. Fluorescently labeled CAF01 was prepared
by addition of Xenolight DiR dissolved in ethanol during the
preparation of the lipid film, resulting in a DiR concentration of
0.025 mg/mL in the final formulation.
Immunizations
Six-to-eight-week old female BALB/c mice (Scanbur, Karlslunde,
Denmark) were allowed to acclimatize for 1 week upon arrival.
All experimental work was approved by the Danish National
Experiment Inspectorate under permit 2016-15-0201-01026 and
was performed in accordance with the European Community
directive 86/609 for the care and use of laboratory animals.
Mice (6–12/group) were immunized once by i.m. or i.pulmon
administration, or by i.m. priming followed by i.pulmon.
pull immunization after an interval of 2 weeks. For the i.m.
immunizations, 5 µg Alexa Fluor R© 647-labeled unadjuvanted
H56 or 5 µg Alexa Fluor R© 647-labeled H56 adjuvanted with DiR-
labeled CAF01 (250/50 µg DDA/TDB) was injected in the right
thigh muscles. For the i.pulmon. immunizations, 10 µg Alexa
Fluor R© 647-labeled unadjuvanted H56 or 10µg Alexa Fluor R© 647-
labeled H56 adjuvanted with DiR-CAF01 (125/25 µg DDA/TDB)
was used, and they were performed as described previously (24).
All vaccines were formulated and administered in a dose-volume
of 50 µL in isotonic Tris buffer. Mice dosed i.m. or i.pulmon. with
50 µL isotonic Tris buffer served as negative controls.
Organ Collection and Cell Preparation
Mice were euthanized 3, 24, or 72 h after the immunizations,
and the lungs, spleens, and draining LNs (inguinal and popliteal
LNs to which vaccines administered i.m. are draining, and
the tracheobronchial and mediastinal LNs to which vaccines
administered i.pulmon. are draining) were isolated. For the
MSI study, mice were euthanized after 6, 24, 48, and 72 h,
and 7, 10, and 14 days. To collect lung tissue, a previously
described protocol was used that involves flushing the pulmonary
circulation and inflating the lung with dispase during tissue
harvest, followed by homogenization and digestion in a DNase
and collagenase solution (26). Briefly, following euthanasia of
mice, the trachea was intubated transorally. The pulmonary
circulation was flushed with 2 mL phosphate-buffered saline
(PBS) followed by instillation of 1 mL dispase (Corning Life
Sciences, Tewksbury, MA, United States). Subsequently, a
volume of 0.7 mL dispase was administered via the endotracheal
catheter, followed by administration of 0.5 mL 1% (w/v)
low-melting-point agarose (Sigma-Aldrich, Brøndby, Denmark)
heated to 50◦C, which served as a semi-solid plug when cooled
to keep the enzyme solution in close proximity to the lung
tissue. The lungs were excised, placed in RPMI 1640 (Sigma-
Aldrich) at 4◦C, and dissociated in gentleMACS C tubes (Miltenyi
Biotec Norden, Lund, Sweden) containing 2 mL RPMI 1640,
5% (v/v) fetal calf serum (FCS, Gibco Thermo Fisher, Hvidovre,
Denmark), 1.5 mg/mL collagenase type IV (Sigma-Aldrich), and
20 units/mL DNase (Sigma-Aldrich) by using the gentleMACS
dissociator (Miltenyi Biotec Norden AB). After 1 h incubation
at 37◦C, the lung pieces were dissociated again by using the
gentleMACS dissociator and centrifuged at 700 × g for 5 min.
Lung cell pellets were forced through a 70 µm cell-strainer
(Falcon, Durham, NC, United States) and washed twice with
RPMI 1640. Single cell suspensions of splenocytes were obtained
by homogenizing the spleens through a nylon-mesh cell-strainer
(Falcon) followed by two washings with RPMI 1640. The LNs
were treated with 2 mL RPMI supplemented with 1 mg/mL
Collagenase type IV and 20 units/mL DNase. After 30 min of
incubation at 37◦C, the LNs were passed through the nylon-
mesh cell-strainer, followed by two washings with RPMI 1640.
For each lung, spleen or LN, 1 × 106 cells (or everything,
if the sample contained less cells) were resuspended in RPMI
1640 supplemented with 5 × 10−5 M 2-mercaptoethanol (Gibco
Thermo Fisher), 1% (v/v) sodium pyruvate (Sigma-Aldrich), 1%
(v/v) penicillin-streptomycin (Gibco Thermo Fisher), 1% (v/v)
HEPES (Gibco Thermo Fisher), and 10% (v/v) FCS (Gibco
Thermo Fisher) and transferred to 96-well, V-bottomed plates.
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Flow Cytometry
Single cell suspensions of lungs, spleen, and LNs from immunized
mice were washed with PBS and resuspended in FACS-buffer
[PBS supplemented with 1% (v/v) fetal calf serum and 0.1%
(w/v) sodium azide]. Following treatment with Fc-block (BD
Biosciences, Lyngby, Denmark), the cells were stained for
30 min at 4◦C for surface markers using mAbs (Supplementary
Table S1). Dead cells were excluded by using the fixable viability
dyes FVS510 or FVS700 (BD). The cells were washed twice,
resuspended in FACS buffer and analyzed using an LSRFortessa
flow cytometer (BD). Gates for the surface markers are based
on fluorescence-minus-one controls. The gating strategy used for
identifying distinct cell populations in the lungs, the spleen, and
the draining lymph nodes is based on previous reports (26–28)
and is further described in the Supplementary Figures S1–S3.
All flow cytometry analyses were performed using the FlowJo
software v10 (Tree Star, Ashland, OR, United States).
Tissue Preparation for Matrix-Assisted
Laser Desorption/Ionization Mass
Spectrometry Imaging (MALDI-MSI)
Following euthanasia, the lungs were removed, snap-frozen on
crushed dry ice and stored at −80◦C until analysis. Analysis
time points selected for imaging were 6, 24, 48, 72, and 96 h
and 7, 10, and 14 days with one mouse analyzed at each
time point and one control animal. The frozen lungs were
mounted onto a cryo-microtome sample specimen disk (Leica
Biosystems Inc., Buffalo Grove, IL, United States) with 5% (w/v)
carboxymethyl cellulose aqueous gel (Sigma-Aldrich) at −24◦C.
The lungs were cut into coronal sections of 18 µm thickness
using a Leica CM3050S cryo-microtome (Leica Microsystems,
Wetzlar, Germany), thaw-mounted onto microscope glass slides
(VWR, Søborg, Denmark) and stored in a −80◦C freezer
until MSI analysis.
Prior to matrix application, the tissue sections were
transferred directly from the freezer to a vacuum desiccator
for 10 min. For the positive ion mode analysis, a solution of
freshly prepared 30 mg/mL DHB in methanol/water (50:50, v/v)
supplemented with 1% (w/v) TFA was used. For the negative
ion mode analysis, a freshly prepared solution of 3 mg/mL
DAN in methanol/water (90:10, v/v) was used. A volume of
300 µL matrix solution was sprayed onto the surface of the
tissue sections using an in-house built pneumatic sprayer with
the sample rotating at 150 rpm (for the application of the
DHB matrix) or 250 rpm (for the application of the DAN
matrix), and the matrix solution was pneumatically sprayed at
a flow rate of 30 µL/min using a nebulizer gas pressure of 2
bar (29). The quality of matrix deposition (homogeneity and
crystal size) was checked by inspection with reflected light
optical microscopy.
MALDI-MSI and Image Analysis
The samples were analyzed using a Thermo Q Exactive Orbitrap
mass spectrometer (Thermo Scientific, Bremen, Germany)
equipped with an AP-SMALDI10 ion source (TransMIT,
Giessen, Germany). The AP-SMALDI10 ion source was
equipped with a nitrogen laser with a wavelength of 337 nm,
and a frequency of 60 Hz, operated using 30 laser pulses per
pixel. Analysis was performed in the positive and negative
ion modes, respectively, using a scan range of 300–1200 Da,
a mass resolving power of 140,000 at m/z 200, a lock mass
of m/z 431.037 corresponding to a signal from the DHB
matrix in the positive ion mode, and a lock mass of m/z
311.130 corresponding to a signal from DAN matrix in the
negative ion mode. Images were acquired at a pixel size
of 100 µm with the ablation craters well separated. After
imaging, the sections were stained with H&E as described
in detail elsewhere (30), and images were acquired using an
optical microscope. The raw files were converted to imzML
files (31), and the MSiReader program was used for image
generation (32). Images were generated with a bin width of
±0.002 Da (±5 ppm). Semi-quantitative data analysis (i.e.,
intensity ratio) was performed for measuring changes in
the abundance of CAF01 lipids [DDA (m/z 550.629) and
TDB (m/z 1025.726)] relative to endogenous tissue lipids,
i.e., phosphatidylcholine {[PC (34:1)], m/z 798.541} and
phosphatidylserine {[PS (38:4)], m/z 810.529}. For calculating
the intensity ratio, a region of interest (ROI) was manually
selected along the lung section, and the mean intensity
of the lipid (i.e., DDA or TDB) in the ROI was divided
by the mean intensity of endogenous tissue lipid (PC or
PS) in that specific ROI. We also analyzed the distribution
of phospholipids, i.e., lysophosphatidylcholines (LysoPC)
and bis(monoacylglycero)phosphate (BMP), sphingolipids
(ceramides), and cholesteryl esters in the lungs following
i.pulmon. administration of CAF01.
Statistical Analysis
Two-way ANOVA followed by Tukey’s multiple comparisons test
was used to analyze the difference between the immunization
groups using the GraphPad Prism software (GraphPad Software
Inc., La Jolla, CA, United States). A value of p < 0.05 was
considered significant.
RESULTS
Mucosal (i.pulmon.) Pull Immunization of
Mice Parenterally (i.m.) Primed With
H56/CAF01 Induces Higher Vaccine
Uptake by Pulmonary APCs as
Compared to i.m. or i.pulmon. Priming
Alone
Similar to our previous study using an i.m. prime – i.pulmon.
pull immunization strategy for the H56/CAF01 vaccine, which
induced strong lung mucosal CD4+ T-cell immunity (24), mice
were primed once by i.m. immunization followed by i.pulmon.
pull immunization. The cellular uptake of Alexa Fluor R©-
labeled H56/DiR-labeled CAF01 in the lungs was evaluated by
multicolor flow cytometry 3, 24, and 72 h post-immunization
and compared with the cellular uptake after i.pulmon. and
i.m. priming immunizations alone (Supplementary Figure S1).
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The fluorescent labeling of CAF01 and its cellular uptake
using flow cytometry was performed as previously reported
(33). H56 was commercially labeled with Alexa Fluor R© 647
as previously reported for ovalbumin (33) and the fluorescent
labeling did not influence the physicochemical properties of
H56 (data not shown). Moreover, we have previously shown
that radiolabeling of H56 did not influence its physicochemical
properties (24). In general, we observed that at 72 h, i.pulmon.
pull immunization induced a significantly higher vaccine uptake
by immune cells in the lungs as compared to i.pulmon. priming
immunization alone (Figure 1 and Supplementary Table S2).
As expected, we did not observe any vaccine+ cells in the
lungs after i.m. priming alone. In addition, there was a rapid
influx of neutrophils into the lungs within the first 24 h after
i.pulmon. pull immunization, and the number of neutrophils
was significantly higher than the number of neutrophils
detected at 24 and 72 h post-immunization in the lungs of
mice only primed by i.pulmon. immunization (Figure 1A).
A comparable trend was observed for alveolar macrophages
(Figure 1B) and inflammatory monocytes (Figure 1C). At 72 h,
a significantly higher number of vaccine+ B cells was detected
following i.pulmon. priming as compared to i.pulmon. pull
immunization (Figure 1D). Among the studied DC subsets,
vaccine+monocyte-derived DCs (moDCs) (Figure 1E), CD11b+
DCs (Figure 1F), and plasmacytoid DCs (pDCs) (Figure 1G)
were detected at significantly higher numbers 72 h after
i.pulmon. pull immunization than after i.pulmon. priming
immunization alone, whereas there was no statistical significant
difference in the number of CD103+ DCs at this time point
(Figure 1H). Similarly, at 72 h, the numbers of vaccine+
interstitial macrophages (Figure 1I) and eosinophils (Figure 1J)
were highest following i.pulmon. pull immunization. We also
assessed the total fraction of each cell subset in the lungs 3,
24, and 72 h post-immunization (Figure 1K), though none of
the subpopulation changes were different between groups. We
did observe a non-significant trend that the neutrophils and
the B cell population were the most abundant cell subsets in
the lungs at the designated time points following the different
immunization regimens. The CD11b+ DCs constituted a major
fraction of the vaccine+ cell subsets, whereas the CD103+
DCs only made up a minor fraction, in particular at 3 and
72 h following i.m. or i.pulmon. immunization. The vaccine
was also associated with pDCs, but vaccine association with
this cell subset was only detectable at 72 h after i.pulmon.
pull immunization. Evaluation of the H56+ uptake by the
immune cells in the lungs (Figure 2) showed almost similar
trends as the vaccine (H56/CAF01) uptake, except that the
numbers of cells taking up the vaccine were 1.5–7.5 times
higher than the numbers of cells displaying detectable H56
uptake. Another major difference was that the majority of
the cellular subsets had taken up H56 as early as 24 h post-
immunization as compared to 72 h in case of H56/CAF01. In
general, the number of vaccine+ and H56+ cells were higher
for the group vaccinated using the i.m. prime – i.pulmon.
strategy as compared to the groups only vaccinated by prime
immunization, which suggests activation of both innate and
memory responses.
H56/CAF01 Parenteral Prime-Airway
Mucosal Pull Immunization Enhances
Vaccine Uptake by Lung Endothelial
Cells and Type I Epithelial Cells as
Compared to Parenteral or Airway
Mucosal Prime Immunization Alone
We also evaluated the uptake of the fluorescently labeled
H56/CAF01 vaccine by pulmonary epithelial cells, endothelial
cells, hematopoietic lineage cells, and lineage-negative cells
(Supplementary Figure S2). No significant differences in the
vaccine uptake by hematopoietic lineage cells could be measured
between the i.pulmon. prime versus i.pulmon. pull immunization
(Figure 3A). At 3 and 24 h post-immunization, no significant
differences were observed in the vaccine uptake by the majority
of the lung cell populations following i.pulmon. priming or
i.pulmon. pull immunization (Figures 3B–E). However, the
number of vaccine+ type II epithelial cells was significantly
higher following i.pulmon. pull immunization than i.pulmon.
priming immunization alone (Figure 3D). At 72 h, a significantly
higher number of vaccine+ endothelial cells (Figure 3B),
type I epithelial cells (Figure 3C), and lineage-negative cells
(Figure 3E) were measured following i.pulmon. pull as compared
to the number of cells after i.pulmon. prime immunization
alone. Evaluation of the total fraction of these pulmonary cell
populations in the lungs (Figure 3F) did not show any significant
differences among the groups. The data showed a non-significant
trend that the hematopoietic cells were largely the dominant
cell subsets in the lungs at the examined time points when
applying different immunization regimens. Endothelial cells and
type I epithelial cells constituted the other fraction of vaccine+
cell subsets. The vaccine+ lineage-negative cells comprised the
dominant fraction of cells 3 h after i.m. immunization, and
this was observed at all time points following the i.m prime –
i.pulmon. pull immunization. We also evaluated the H56 uptake
by the endothelial cells and epithelial cells in the lungs (Figure 4)
and found an almost similar cellular distribution as for the
H56/CAF01 uptake. However, the numbers of cells taking up the
vaccine (H56 + CAF01) were in general 2–3.75 times higher than
the number of cells that displayed detectable levels of H56 uptake.
Differential Splenic Cellular
Pharmacokinetics of H56/CAF01 Upon
Prime and Prime-Pull Immunization
We also assessed the cellular uptake of the H56/CAF01 vaccine
by innate myeloid cells and APCs in the spleen (Supplementary
Figure S3). Overall, we found differences in the vaccine
uptake by splenocyte populations when applying the three
different immunization strategies (Figure 5 and Supplementary
Table S2). At 3 h post-i.m. immunization, a significantly higher
number of vaccine+ neutrophils was observed as compared to
mucosal immunizations (Figure 5A). At 24 h, significantly higher
numbers of pDCs (Figure 5B) and inflammatory monocytes
(Figure 5C) were observed after i.pulmon. and i.m. – i.pulmon.
immunization as compared to i.m. immunization alone. No
other differences were observed at 3 and 24 h among the
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FIGURE 1 | Airway mucosal pull immunization after parenteral immunization with H56/CAF01 increases vaccine uptake by innate myeloid cells in the lungs as
compared to parenteral or airway mucosal priming alone. BALB/c mice were immunized with Alexa Fluor R© 647-labeled H56/DiR-labeled CAF01 via the i.m. or
i.pulmon. or i.m. – i.pulmon. routes, and the vaccine uptake by lung cells was assessed by flow cytometry 3, 24, and 72 h post-immunization. Numbers of vaccine+
(H56+/CAF01+) (A) neutrophils (Ly6G+), (B) alveolar macrophages (F4/80+CD11b-), (C) inflammatory monocytes (Ly6C+CD11b+), (D) B cells (CD19+), (E) moDCs
(CD11c+F4/80+CD11b+CD64+), (F) CD11b+ DCs (CD11c+CD11b+), (G) pDCs (CD11c+Ly6C+F4/80-CD11b-), (H) CD103+ DCs (CD11c+CD11b-CD103+), (I)
interstitial macrophages (F4/80+CD11b+), and (J) eosinophils (SiglecF+) in the lungs. (K) Fraction of vaccine+ (H56+/CAF01+) cells in the lungs at 3, 24, and 72 h
post-immunization. Data points represent n = 4, and they display mean values ± SEM. **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. i.pulmon. immunization via
two-way ANOVA with Tukey’s post-test.
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FIGURE 2 | H56 uptake by different immune cells in the lungs following prime or prime – pull immunization with H56/CAF01. BALB/c mice were immunized with
Alexa Fluor R© 647-labeled H56/DiR-labeled CAF01 via i.m. or i.pulmon. or i.m. – i.pulmon. routes, and the H56+ uptake by lung cells was assessed by flow
cytometry 3, 24, and 72 h post-immunization. Numbers of H56+ (A) neutrophils (Ly6G+), (B) alveolar macrophages (F4/80+CD11b-), (C) inflammatory monocytes
(Ly6C+CD11b+), (D) B cells (CD19+), (E) moDCs (CD11c+F4/80+CD11b+CD64+), (F) CD11b+ DCs (CD11c+CD11b+), (G) pDCs (CD11c+Ly6C+F4/80-CD11b-),
(H) CD103+ DCs (CD11c+CD11b-CD103+), (I) interstitial macrophages (F4/80+CD11b+), and (J) eosinophils (SiglecF+) in the lungs. (K) Fraction of H56+ cells in
the lungs at 3, 24 and 72 h post-immunization. Data points represent n = 2, and they display mean values ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 vs. i.pulmon. immunization via two-way ANOVA with Tukey’s post-test.
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FIGURE 3 | Intramuscular (i.m.) prime-intrapulmonary (i.pulmon.) pull immunization with H56/CAF01 increases vaccine uptake by lung endothelial cells and type I
epithelial cells as compared to either i.m. or i.pulmon. immunization alone. BALB/c mice were immunized with Alexa Fluor-labeled H56/DiR-labeled CAF01 via the
i.m. or i.pulmon. or i.m. – i.pulmon. routes, and vaccine uptake by lung cells was assessed by flow cytometry 3, 24, and 72 h post-immunization. Numbers of
vaccine+ (H56+/CAF01+) (A) hematopoietic lineage cells (CD45+CD31-CD326-), (B) endothelial cells (CD45-CD31+CD326-), (C) type I epithelial cells
(CD45-CD31-CD326+CD74-Podoplanin+), (D) type II epithelial cells (CD45-CD31-CD326+CD74+Podoplanin-), and (E) lineage-negative cells
(CD45-CD31-CD326-) in the lungs. (F) Fraction of vaccine+ (H56+/CAF01+) cells in the lungs at 3, 24, and 72 h post-immunization. Data points represent mean
values ± SEM (n = 4). ***p < 0.001, ****p < 0.0001 vs. i.pulmon. immunization via two-way ANOVA with Tukey’s post-test.
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FIGURE 4 | H56 uptake by epithelial cells, endothelial cells, hematopoietic lineage cells, and lineage-negative cells in the lungs following prime or prime – pull
immunization with H56/CAF01. BALB/c mice were immunized with Alexa Fluor R© 647-labeled H56/DiR-labeled CAF01 via the i.m. or i.pulmon. or i.m. – i.pulmon.
routes, and the H56+ uptake by lung cells was assessed by flow cytometry 3, 24 and 72 h post-immunization. Numbers of vaccine+ (H56+/CAF01+) (A)
hematopoietic lineage cells (CD45+CD31-CD326-), (B) endothelial cells (CD45-CD31+CD326-), (C) type I epithelial cells (CD45-CD31-CD326+CD74-Podoplanin+),
(D) type II epithelial cells (CD45-CD31-CD326+CD74+Podoplanin-), and (E) lineage-negative cells (CD45-CD31-CD326-) in the lungs. (F) Fraction of H56+ cells in
the lungs at 3, 24, and 72 h post-immunization. Data points represent n = 2 and display mean values ± SEM. *p < 0.05, ****p < 0.0001 vs. i.pulmon. immunization
via two-way ANOVA with Tukey’s post-test.
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FIGURE 5 | Differential vaccine uptake by innate myeloid and antigen-presenting cells following parenteral or mucosal prime and parenteral prime-mucosal pull
immunization with H56/CAF01. BALB/c mice were immunized with Alexa Fluor R©-labeled H56/DiR-labeled CAF01 via the i.m. or i.pulmon. or i.m. – i.pulmon. routes,
and the vaccine uptake by spleen cells was assessed by flow cytometry 3, 24, and 72 h post-immunization. Numbers of vaccine+ (H56+/CAF01+) (A) neutrophils
(Ly6G+), (B) pDCs (CD11c+Ly6C+F4/80-CD11b-), (C) inflammatory monocytes (Ly6C+CD11b+), (D) moDCs (CD11c+F4/80+CD11b+CD64+), (E) CD8α+ DCs
(CD11c+CD11b-CD8α +), (F) CD11b+ DCs (CD11c+CD11b+), (G) B cells (CD19+), (H) macrophages (F4/80+CD11b+), and (I) eosinophils (SiglecF+) in the
spleen. (J) Fraction of vaccine+ (H56+/CAF01+) cells in the spleen at 3, 24, and 72 h post-immunization. Data points represent n = 4, and they display mean
values ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. i.m. immunization via two-way ANOVA with Tukey’s post-test.
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FIGURE 6 | H56 uptake by splenic cells following parenteral or airway mucosal prime or parenteral prime – airway mucosal pull immunization with H56/CAF01.
BALB/c mice were immunized with Alexa Fluor R© 647-labeled H56/DiR-labeled CAF01 via i.m. or i.pulmon. or i.m. – i.pulmon. routes, and the H56+ uptake by spleen
cells was assessed by flow cytometry 3, 24, and 72 h post-immunization. Numbers of (A) neutrophils (Ly6G+), (B) pDCs (CD11c+Ly6C+F4/80-CD11b-), (C)
inflammatory monocytes (Ly6C+CD11b+), (D) moDCs (CD11c+F4/80+CD11b+CD64+), (E) CD8α+ DCs (CD11c+CD11b-CD8α +), (F) CD11b+ DCs
(CD11c+CD11b+), (G) B cells (CD19+), (H) macrophages (F4/80+CD11b+), and (I) eosinophils (SiglecF+) in the spleen. (J) Fraction of H56+ cells in the spleen at
3, 24, and 72 h post-immunization. Data points represent n = 2, and they display mean values ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. i.m. immunization
via two-way ANOVA with Tukey’s post-test.
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different immunization strategies. At 72 h, the vaccine+ moDCs
(Figure 5D), CD8α+ DCs (Figure 5E), and CD11b+ DCs
(Figure 5F) were higher for all immunization groups than at
3 and 24 h, but were not different among the immunization
strategies used. A significantly higher number of vaccine+
CD8α+ DCs were observed following i.pulmon. immunization
as compared to the i.m. immunization. The numbers of vaccine+
neutrophils (Figure 5A), pDCs (Figure 5B), and inflammatory
monocytes (Figure 5C) at 72 h decreased, as compared to the
number of vaccine+ cells measured 24 h post-immunization,
and the numbers of cells were not different among the
groups. For mice vaccinated by i.m. immunization, significantly
higher numbers of vaccine+ B cells (Figure 5G), macrophages
(Figure 5H), and eosinophils (Figure 5I) were detected, as
compared to the numbers of cells measured after i.pulmon.
prime or pull immunization at 72 h. Among the total fraction of
vaccine+ splenic cell types at 3, 24, and 72 h post-immunization
(Figure 5J), we did not observe any significant differences
between the groups. However, the percentage subpopulations of
all the H56+ splenic cells (Figure 6J) were statistically higher
(p < 0.05) following 24 h of i.m./i.pulmon. immunization
as compared to i.m. immunization. We did observe a non-
significant trend that the neutrophils, macrophages and B cells
were the predominant cell populations taking up the vaccine,
independently of the immunization strategy. The CD11b+ DCs
and moDCs constituted the dominant DC subsets, in particular
at 72 h post-immunization. In general, there was a diversified
participation of innate myeloid cells and APCs in the vaccine
uptake in the spleen following i.pulmon. immunization. For the
H56+ uptake (Figure 6), almost similar trends were apparent, as
compared to the vaccine uptake, but the numbers of cells taking
up the vaccine were 1.2-8 times higher than the numbers of cells
displaying detectable H56 uptake.
Mucosal Pull Immunization of Mice
Parenterally Primed With H56/CAF01
Promotes Upregulation of CD86
Expression by Dendritic Cells in the
Lung-Draining Lymph Nodes as
Compared to Parenteral or Mucosal
Prime Immunization Alone
Clear differences were observed in the vaccine uptake by
immune cells in the lungs of mice vaccinated using different
immunization strategies. Therefore, we investigated if differences
in the draining lymph node innate environment after mucosal
pull immunization may contribute to the differences measured in
the vaccine uptake when using the three immunization strategies
(Supplementary Figure S3) and to the higher cell-mediated and
humoral immune responses following i.m. prime – i.pulmon. pull
immunization, as reported previously (24). We found that the
activation states, assessed as the CD86 surface expression by B
cells (at 24 h, Figure 7A), moDCs (at 72 h, Figure 7B), CD8α+
DCs (at 24 h, Figure 7C), and CD11b+ DCs (at 72 h, Figure 7D)
in the tracheobronchial lymph nodes (TLNs) and mediastinal
lymph nodes (MLN) draining the lungs in i.m. prime and
i.pulmon. pull immunized mice, were significantly higher than
the activation states after i.m. or i.pulmon. immunization alone.
There were no differences between the immunization strategies
in the CD86 surface expression by pDCs (Figure 7E) and
macrophages (Figure 7F) in the TLNs and MLNs. Interestingly,
B cells (Figure 7G) and pDCs (Figure 7K) were activated distal
to the site of immunization in the inguinal lymph nodes (ILNs)
and the popliteal lymph nodes (PLNs) at 24 h post-prime-pull
immunization, and only DCs showed increased activation after
i.m. immunization. However, there was no difference in the
surface expression of CD86 between the immunization strategies
in moDCs (Figure 7H), CD8α+ DCs (Figure 7I), CD11β+ DCs
(Figure 7J), and macrophages (Figure 7L). Overall, there was
an increased activation state of vaccine+ DCs in the lymph
nodes draining the lungs after i.m. prime – i.pulmon. pull
immunization with H56/CAF01.
A Uniform DDA Distribution and Signal
Intensity in the Lungs Can Be Detected
for at Least 2 Weeks After
Intrapulmonary Administration of CAF01
To investigate the spatiotemporal distribution of the CAF01
constituent lipids (DDA and TDB) in the lungs, MALDI-MSI was
performed on cryo-sections of lung tissue isolated 6, 24, 48, and
72 h, and 7, 10, and 14 days after i.pulmon. administration of
CAF01 to mice, and we compared the results with the signals
obtained from cryo-sections of lungs from naïve mice. At these
specific time points, we then compared the signal intensity
ratios between DDA and TDB, respectively, and the endogenous
lipid PC (34:1) in the positive ion mode in a semi-quantitative
way. We found that DDA (m/z 550.62) could be detected
at all examined time points after i.pulmon. administration of
CAF01 (Figure 8). In addition, DDA displayed a homogeneous
tissue distribution in the lungs at all examined time points at
comparable signal intensities. Lung cryo-sections from negative
control mice did not display any detectable MS signals of DDA
and TDB. Ionized PC (34:1) (m/z 798.541) was also uniformly
expressed in the lung cryo-sections at all investigated time points
(Supplementary Figure S4). Co-localization analysis showed
that DDA and PC (34:1) were present together in the lung
sections (Figure 8A), and the signal intensity ratio of DDA
and PC (34:1) appeared rather constant throughout the study
(Figure 8B). As compared to DDA, the signal intensity for
TDB (m/z 1025.726) was relatively lower, and the signal was
apparently not distributed homogeneously in the lung sections
(Supplementary Figure S5A). The signal intensity ratio of TDB
relative to PC (34:1) increased from 6 h and reached a maximum
at 48 h post-administration, after which the intensity ratio
remained low until day 14, where the TDB signal was no longer
detectable (Supplementary Figure S5B).
Increased BMP Lipids in Alveloar
Macrophages Following Intrapulmonary
Administration of CAF01 Is Suggestive of
Altered Phagocytic Activity
From the same imaging experiments, images were generated
of selected biomarker phospholipids, i.e., BMP and lysoPC,
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FIGURE 7 | The expression of CD86 by dendritic cells in the lung-draining lymph nodes is upregulated after parenteral prime and mucosal pull immunization of mice
with H56/CAF01, as compared to the CD86 levels in mice vaccinated by parenteral or mucosal prime immunization alone. BALB/c mice were immunized with Alexa
Fluor R©-labeled H56/DiR-labeled CAF01 via the i.m. or i.pulmon. or i.m. – i.pulmon. routes, and the vaccine uptake in the lymph nodes draining the i.m.
administration site [inguinal (ILN) and popliteal (PLN)] or the i.pulmon. administration site [tracheobronchial (TLN) and mediastinal (MLN)] was assessed by flow
cytometry 3, 24, and 72 h post-immunization. The relative surface expression of CD86 by antigen-presenting cells was assessed and expressed as mean
fluorescence intensity (MFI). CD86 surface expression by vaccine+ (H56+/CAF01+) (A) B cells (CD19+), (B) moDCs (CD11c+F4/80+CD11b+CD64+), (C) CD8α+
DCs (CD11c+CD11b-CD8α+), (D) CD11b+ DCs (CD11c+CD11b+), (E) pDCs (CD11c+Ly6C+F4/80-CD11b-), and (F) macrophages (F4/80+CD11b+) in the TLN
and MLN, and (G) B cells (CD19+), (H) moDCs (CD11c+F4/80+CD11b+CD64+), (I) CD8α+ DCs (CD11c+CD11b-CD8α+), (J) CD11b+ DCs (CD11c+CD11b+),
(K) pDCs (CD11c+Ly6C+F4/80-CD11b-), and (L) macrophages (F4/80+CD11b+) in the ILN and PLN at 3, 24, and 72 h post-immunization. Data points represent
n = 4, and they display mean values ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. i.m. immunization via two-way ANOVA with Tukey’s post-test.
and sphingolipids, i.e., ceramides, in the lungs after i.pulmon.
administration of CAF01. BMP is a recognized biomarker
of phagocytozing macrophages (34), and it is abundantly
expressed in the late endosomes and lysosomes of alveolar
macrophages (35), while lysoPC (36) and ceramides (37) are
known biomarkers of inflammation. We observed that 6 h
after i.pulmon. administration of CAF01, the BMP (22:6/22:6,
m/z 865.503) expression level in the lungs was comparable
to the BMP level measured for control animals (Figure 9A).
However, from 24 h and onward, the BMP signal increased
consistently reaching a maximum at day 10 of the study,
after which it was decreased at day 14. The ionized PS (38:4)
(m/z 810.529), which is the most abundant phosphatidylserine
species in the lungs (38), was expressed in the lung sections
at all studied time points (Supplementary Figure S6). Analysis
of the signal intensity ratio of BMP (22:6/22:6) as compared
to PS (38:4) (m/z 810.529) showed that the intensity ratio
of BMP/PS was increased from 24 h post-administration,
reached a threshold at day 10 of the study, after which it
was decreased at day 14 (Figure 9B). The increased level of
BMP after i.pulmon. administration of CAF01 therefore suggests
an altered phagocytic activity in alveolar macrophages. We
did not observe any expression of ceramides and cholesteryl
esters at the investigated time points after administration of
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FIGURE 8 | Uniform distribution and signal intensity of dimethyldioctadecylammonium (DDA) bromide in cryo-sections of lungs of mice, which have been dosed
intrapulmonary (i.pulmon.) with CAF01. BALB/c mice were immunized once with CAF01 via the i.pulmon. route, and matrix-assisted laser desorption/ionization mass
spectrometry imaging (MALDI-MSI) was performed on lung cryo-sections at 6, 24, 48, and 72 h, and 7, 10, and 14 days after the immunization. Untreated mice
served as negative control. (A) Hematoxylin and eosin (H&E) staining (left panels), MALDI-MSI-based distribution of DDA [M + H]+ (m/z 550.629 ± 0.002, middle
panels), and mass spectrometry (MS) co-localization images (right panels) of DDA [M + H]+ (green) and PC (34:1) [M + K]+ (m/z 798.541 ± 0.002) (blue) in the lungs
at different time points after i.pulmon. administration of CAF01. (B) Signal intensity ratios between DDA and PC (34:1) at different time points of the study, which
were calculated after drawing a region of interest (ROI) across the lung sections and comparing the MS signal intensities in the respective ROIs. All images were
measured in the positive ion mode by MALDI-MSI at a pixel size of 100 µm.
CAF01 (data not shown). The phospholipid LysoPC (16:0)
(m/z 518.323) was primarily distributed homogeneously in
the lungs following CAF01 administration (Supplementary
Figure S7A). Analysis of the signal intensity ratio of LysoPC
(16:0)/PC (34:1) confirmed this observation. The intensity ratio
of LysoPC/PC after administration of CAF01 remained low
until day 10, or at the same level at day 14, compared to
negative control lungs (Supplementary Figure S7B). This data
therefore suggests that i.pulmon. administration of CAF01 does
not induce any apparent inflammation or tissue damage in the
lungs because the LysoPC and ceramides levels are not influenced
by CAF01 administration.
DISCUSSION
Here, we investigated further our previous finding that
parenteral prime and airway mucosal pull immunization with the
H56/CAF01 vaccine induces higher humoral and cell-mediated
immune responses than parenteral immunization alone (24)
by providing a cellular basis that may explain the enhanced
immunogenicity. We show that the i.m. prime – i.pulmon.
pull immunization regimen with H56/CAF01 induces a higher
vaccine uptake by pulmonary APCs, endothelial cells, and type
I epithelial cells as well as splenic inflammatory macrophages
as compared to the vaccine uptake measured after i.m. and
i.pulmon. immunization, respectively. In addition, there is an
increased activation state of vaccine+ DCs and B cells in the lung-
and intramuscular-draining lymph nodes following i.m. prime –
i.pulmon. pull immunization with H56/CAF01, as compared to
the activation state measured after immunization using the i.m.
and i.pulmon. routes of administration, respectively. A major
difference between the evaluated immunization strategies is the
activation of innate immunity after i.m. and i.pulmon. prime
immunization alone, as compared to the activation of both innate
and memory immune responses after i.m. prime – i.pulmon pull
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FIGURE 9 | Increased bis(monoacylglycero)phosphate (BMP) expression in the lungs of mice dosed intrapulmonary (i.pulmon.) with CAF01. BALB/c mice were
immunized once with CAF01 via the i.pulmon. route, and matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was performed on
lung cryo-sections collected 6, 24, 48, 72 h, and 7, 10, and 14 days after immunization. Untreated mice served as negative control. (A) Hematoxylin and eosin (H&E)
staining (left panels) and MALDI-MSI-based distribution of BMP (22:6/22:6) [M + H]- (m/z 865.503, right panels) in cryo-sections of lungs isolated at different time
points after i.pulmon. dosing with CAF01. (B) Signal intensity ratios between BMP and PS (38:4) [M + H]- (m/z 810.529 ± 0.002) at different time points of the study,
which were calculated by drawing a region of interest (ROI) across the lung sections and comparing the MS signal intensities in the respective ROIs. All images were
measured in the negative ion mode by using MALDI-MSI at a pixel size of 100 µm.
immunization, in particular at the 24 h time point of the study.
Importantly, we show for the first time that MSI is a useful
tool to investigate the biodistribution of a lipid-based vaccine
adjuvant. We report that following pulmonary immunization,
CAF01 is homogeneously distributed in the lung parenchyma
and is present in the lungs for at least 2 weeks without
inducing any measurable local tissue damage or inflammation.
We further report an increased BMP signal in the lungs following
immunization, which in ischemic brain tissue has been shown
to correlate with an increased phagocytic activity of cerebral
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macrophages (34). Hence, the increased BMP activity measured
in the lungs after administration of CAF01 may be correlated with
an altered phagocytic activity in alveolar macrophages.
The lungs are highly vascularized with a large surface area
and an extensive network of immune cells surveilling the mucosa
against microbial attacks, which make lung tissue an attractive
target for the administration of subunit vaccine antigens and
immunopotentiating adjuvants (39). Subunit vaccines may elicit
immunopotentiating effects by interacting with the highly
specialized network of immune cells, e.g., DCs and macrophages
that capture the vaccines via pattern-recognition receptors and
transport them (antigen + adjuvant) to the regional lymph
nodes, where antigen-specific T cell activation takes place
(14). T cell-mediated protection against Mtb is recognized to
be dependent on the ability of the antigen-specific T-cells
to home back to the lung parenchyma and directly interact
with infected cells (40, 41). Accordingly, a number of airway
mucosal immunization strategies, based on either mucosal BCG
vaccination or heterologous mucosal vaccination with viral
vectors encoding Mtb antigens following BCG priming, have
been tested and found to enhance the number of protective
lung-resident T cells against TB (42–44). Hence, pulmonary
delivery of subunit vaccines represents an attractive strategy for
inducing antigen-specific T cell immunity in the lungs (39, 45).
We envisage to use this strategy for immunization of adolescents
and adults with H56/CAF01 vaccine. BCG is administered to
newborns immediately after birth and has over 70% protective
efficacy against tuberculous meningitis and miliary TB (46), while
in adults, BCG vaccination fails to completely protect against
pulmonary TB and has a very variable protective efficacy (0–
80%) (47). BCG vaccination also reduces mortality in newborn
and children because of non-specific cross-protection induced by
this vaccine against other unrelated pathogens (48). Therefore,
keeping in view the beneficial effects of BCG vaccination in
children, our long term strategy is to boost the BCG-primed
immune responses (in infants and neonates) with parenteral
prime and mucosal pull immunization of H56/CAF01 vaccine (in
adolescents and adults).
Recently, we demonstrated that parenteral prime and
i.pulmon. pull immunization with the H56/CAF01 vaccine
induces significantly higher airway mucosal as well as systemic
IgA and polyfunctional CD4+ T cells as compared to parenteral
prime and pull immunization (24). However, the cellular basis
of this increased immune response after parenteral prime
and mucosal pull immunization was unknown. The results of
our current work provide strong evidence that this enhanced
immunity may be by virtue of an increased vaccine uptake by
pulmonary APCs, including DCs and macrophages, and/or an
enhanced activation of DCs in the lung-draining lymph nodes. In
the lungs, several DC subsets and macrophages reside possessing
specialized functions with respect to antigen uptake, presentation
and initiation of immune responses (49). In the steady state,
the lungs are populated by two major subsets of conventional
DCs (cDCs), i.e., CD103+ and CD11b+ cDCs, and pDCs,
while moDCs migrate into the lung parenchyma in response to
inflammation (28). In our study, the H56/CAF01 vaccine is taken
up by respiratory tract APCs, but the extent of uptake is highly
dependent on the specific immunization strategy. Pulmonary
DCs and macrophages were strongly positive for H56/CAF01
administered by applying the parenteral prime – mucosal pull
immunization strategy as compared to the H56/CAF01 levels
measured after parenteral immunization alone.
Using virosomes and liposomes as delivery systems without
or with conjugated ovalbumin, it has previously been shown
that DCs and macrophages take up equally well nanoparticles
administered intranasally (50). However, another study reported
enhanced uptake of latex particles by alveolar macrophages, as
compared to pulmonary DCs, after intranasal administration
(51). Recently, airway mucosal pull immunization by H56/CAF01
immunization was demonstrated to induce significantly
increased numbers and activation state of alveolar macrophages
in the lungs (23). At the earliest time point investigated in the
present study, i.e., 3 h after administration, our measurements
did not show any detectable vaccine uptake in the airways or
trafficking to the lung-draining LNs, as reported previously (12).
Only 24 h after immunization, there were visible differences in
the vaccine uptake between the different APCs, depending on the
specific immunization strategy. We also observed a significantly
higher number of vaccine+ neutrophils following mucosal
pull immunization as compared to the number of vaccine+
neutrophils after single immunizations. Among the visceral
organs, the lungs contain the highest proportion of neutrophils,
which might facilitate the activation and differentiation of
antigen-specific CD4+ T cells via cross-talk with DCs (52, 53).
Therefore, our results show that there are distinct differences
in the vaccine uptake by innate myeloid APCs and B cells,
depending on the specific immunization strategy (prime
versus prime – pull). Similarly, a high phenotypic diversity
of neutrophils, monocytes, and DCs was observed between
prime and pull immunization of cynomolgus macaques with the
modified vaccinia virus Ankara (54).
In addition to professional APCs, a variety of other cell types
may present antigens to T-helper cells, including epithelial cells
(55, 56). Lung epithelial cells can present antigens, and they play
an important role for the induction of local immune responses
in the lungs (55, 57). We found that mucosal pull immunization
induces a higher number of vaccine+ type II epithelial cells
within 3 h and a higher number of type I epithelial cells at 72 h
post-immunization as compared to parenteral immunization
alone. Both type I (57) and II (58) epithelial cells possess the
ability to present antigens, but they differ in their expression
levels of major histocompatibility complex II molecules with
higher expression levels in type II cells than in type I cells
(57). We also observed lower major histocompatibility complex
II expression in vaccine+ type I epithelial cells in this study
(data not shown). The potential role of lung epithelial cells
in antigen capture and presentation in immune responses is
restricted to stimulate T cells previously presented to antigens by
other APCs (59, 60). We found that the hematopoietic lineage
and lineage-negative cells took up the vaccine, in particular at
72 h after immunization. Lineage-negative cells primarily include
fibroblasts, smooth muscle cells and mesenchymal stem cells (26).
The mesenchymal stem cells have the capability to capture and
release antigens, which are subsequently captured by APCs (61).
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The distinct differences in vaccine uptake by pulmonary
immune cells after vaccine administration applying the three
different immunization strategies correlated well with the
subsequent activation state of DCs measured in the draining
LNs. Previously, it has been shown that the activation state of
CAF04- and CAF09-induced CD4+ and CD8+ T cells coincided
with the activation of resident and migratory DCs in the
spleen and the draining LNs after parenteral immunization
(33). In the lung-draining LNs, resident CD8α+ and migratory
CD11b+ DCs were significantly activated at 24 and 72 h after
mucosal pull immunization, respectively, than after parenteral
immunization. This increased activation state of vaccine+ DCs
in the lung-draining lymph nodes (TLN + MLN) by i.m. prime –
i.pulmon. pull immunization with H56/CAF01 supports our
previous results where we observed that this immunization
strategy induces high lung mucosal and systemic antibody and
CD4+ responses (24). On the other hand, in the LNs draining
the i.m. site of immunization (ILN + PLN), no significant
differences between the activation state of CD8α+ and CD11b+
DCs were observed among the different immunization strategies
used. Interestingly, B cells and pDCs are significantly activated
in ILN + PLN at 24 h post-prime-pull immunization, and
the fact that only DCs showed increased activation after i.m.
immunization is supported by previous studies (62). Similarly,
we found that all immunization strategies used for administering
the H56/CAF01 vaccine promote differential cellular uptake
by innate myeloid APCs present in the spleen. Our previous
results show that i.m. prime – i.pulmon. pull immunization
with H56/CAF01 induces highly comparable antibody and
CD4+ responses in the spleen as the i.m. immunization
(24). Overall, there were marked differences in the vaccine
uptake by innate myeloid APCs, epithelial cells, and B cells
and in the activation state of APCs between prime and
prime – pull immunization with the H56/CAF01 vaccine.
Recently, it was shown that the innate myeloid cells following
the prime – pull with the modified vaccinia virus Ankara
displayed higher activation states and enhanced expression
of molecules involved in phagocytosis, antigen presentation,
co-stimulation, chemotaxis, and inflammation (54). Recently,
we showed that mucosal (intranasal) pull immunization of
H56/CAF01 immunization significantly increased the early lung-
localized vaccine T-cell response and increased early protection
to a pulmonary Mtb challenge in mice (23). Therefore, our
results demonstrating an improved antigen uptake and s stronger
immune response following i.pulmon. pull immunization of
H56/CAF01 immunization (24) are certainly promising for our
efforts to develop a thermostable, dry powder-based H56/CAF01
vaccine intended for i.pulmon. immunization of BCG-primed
individuals (63).
Mass spectrometry imaging can be used to identify the
distribution and expression levels of molecules, e.g., biomarkers,
peptides and proteins, and metabolites or drugs in tissue
sections with high sensitivity and specificity, without the need
to label the analyte (34, 64). This imaging technique can also
be used to identify the spatiotemporal distribution of different
phospholipids in various tissues, including the lungs (34, 65).
Using SPECT-CT imaging, we have previously measured the
pharmacokinetics of CAF01 for up to day 6 after pulmonary
administration (24). However, there is still insufficient data
on the long-term fate and safety of CAF01 administered in
the respiratory tract. Here, we show using MSI that DDA
distributes uniformly in the lungs and is detectable for at least
2 weeks post-i.pulmon. administration of CAF01. Both DDA and
TDB co-localize with the endogenous phospholipids PC (34:1)
in the positive ion mode and PS (38:4) in the negative ion
mode. The phospholipid lysoPC (16:0) (36) and the sphingolipid
ceramide (37) are well-known biomarkers of inflammation and
local tissue damage, respectively. The absence of enhanced
ceramide expression in the lungs of mice immunized with
CAF01, and the lack of difference in the expression levels of
LysoPC between the immunized mice and the negative control
animal, suggest that i.pulmon. administration of CAF01 may
be safe and does not induce any apparent inflammation in
the lungs during the investigated time period. Using intranasal
(66, 67) and i.pulmon. immunization (24, 68), our previous
results have consistently shown the safety of immunization with
the CAF01 adjuvant in preclinical animal models and most
recently in phase I clinical trials in humans following intranasal
immunization with a Chlamydia antigen (69). Therefore, in
this study we did not expect any difference in the number of
inflammatory cells among the immunization strategies and did
not compare histopathological changes in lung tissue sections.
BMP (22:6/22:6) is a negatively charged glycerophospholipid,
which is primarily localized in the late endosomes/lysosomes
(70). The BMP content is enriched in alveolar macrophages, as
compared to other cell types, and it is primarily localized in
phagosomes (35). BMP (22:6/22:6) has been shown to co-localize
with the macrophage biomarker CD11b in ischemic brain tissue,
and it is a reported biomarker for phagocytozing macrophages
(34). The increased level of BMP after i.pulmon. administration
of CAF01 liposomes measured in our study suggests an increased
phagocytic activity in alveolar macrophages. In addition, the flow
cytometry data demonstrates an increased number of alveolar
macrophages 24 and 72 h after i.pulmon. administration of the
H56/CAF01 vaccine. Hence, these results collectively suggest that
after i.pulmon. administration of CAF01, there is (i) an increased
alveolar macrophage activity, as well as (ii) an increased number
of alveolar macrophages that takes up the vaccine. In a previous
study, cholesteryl esters were shown to co-localize with BMP
during resolution of cerebral inflammation due to phagocytosis of
cholesterol-containing dead cells or cell debris (34). However, in
our study, the BMP expression was not accompanied by increased
levels of cholesteryl esters. The lack of cholesteryl ester expression
in our study suggests that (i) there is no increased phagocytosis of
dead cells following CAF01 administration in the lungs, and (ii)
applying this administration route does not cause any measurable
local inflammation.
In this study, we chose to investigate multiple time points
by MSI post-i.pulmon. administration of CAF01, rather than
including more animals in each group and fewer time points.
We believe that this imaging method is a very robust method
for evaluating even low doses/expression levels of proteins,
lipids and their metabolites. However, to improve the statistical
strength of our data, more biological replicates should be
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included in future studies. In addition, commonly investigated
biomarkers for systemic inflammation, e.g., plasma C-reactive
protein and interferon-γ inducible protein-10 concentrations,
should be evaluated to investigate further the safety of
pulmonary vaccination.
CONCLUSION
In conclusion, we show that there are pronounced differences
in the vaccine uptake by innate myeloid APCs in the lungs
and the spleen and epithelial cells in the lungs, and in the
activation state of APCs in the lung-draining lymph nodes
after i.m. prime and i.pulmon. mucosal pull immunization with
the H56/CAF01 vaccine, as compared to i.m. or i.pulmon.
priming alone, which suggests activation of both innate and
memory response by prime – pull immunization. Using
phospholipid analysis by MALDI-MSI, we further conclude
that airway mucosal immunization with H56/CAF01 is a safe
immunization approach, which is critical to consider in the
rational design of vaccines for pulmonary delivery. Overall,
the differences in vaccine uptake by innate myeloid cells
and activation of APCs among the different immunization
strategies described here can be valuable to tailor vaccine-
induced immunity.
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